Last updated on April 2018

Study of LXH254 and LTT462 in NSCLC

Brief description of study

To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 and LTT462 combination and for the LXH254 and trametinib combination.

Clinical Study Identifier: NCT02974725

Contact Investigators or Research Sites near you

Start Over

Novartis Pharmaceuticals

Novartis Investigative Site
Villejuif Cedex, France
  Connect »